Acadia Pharmaceuticals Inc. (ACAD) saw its stock price drop by 4.11% following the announcement of Catherine Owen Adams as its new CEO. Adams, who brings extensive experience from Bristol Myers Squibb and Johnson & Johnson, is expected to lead Acadia through its next growth phase. This news comes as the company continues to navigate the market with its approved products, NUPLAZID and DAYBUE.